When the surrounding water dilutes, a shrimp’s cells face a triple assault. Osmotic stress makes cells swell as water rushes in, disrupting the delicate water balance inside tissues. Ionic stress impairs the channels and enzymes that keep sodium, potassium and chloride in check. And oxidative stress generates reactive oxygen species that oxidize proteins, inactivate enzymes and damage DNA. Together, these pressures can trigger apoptosis, alter membrane fluidity and ultimately kill the animal. Understanding how shrimp blunt this cascade is not just an academic exercise; it directly determines survival, growth and productivity on farms that supply a large share of the world’s seafood protein.

The review’s first major theme is how shrimp perceive salinity change in the first place. G protein-coupled receptors, or GPCRs, are abundant in penaeid genomes: the L. vannamei reference genome contains 457 GPCR genes, and transcriptome curation in P. monodon identified three major classes totaling 350 members. Intriguingly, the authors caution that direct evidence for GPCRs acting as primary salinity sensors remains limited. Instead, these receptors are more plausibly engaged indirectly, as salinity shifts alter the availability of neuroendocrine and paracrine ligands. Once activated, GPCRs funnel signals through cAMP, protein kinase A, PI3K-Akt and MAPK cascades. Transcriptomic profiling of P. monodon gills under chronic low salinity showed differentially expressed genes mapping to PI3K-Akt, MAPK and calcium signaling pathways, supporting a role for GPCR-linked cascades in gill-centered osmoregulatory acclimation.

Calcium signaling emerges as a second, faster perception module. As extracellular osmotic pressure drops, calcium-permeable membrane channels open and calcium is also mobilized from intracellular stores such as the endoplasmic reticulum, producing a transient spike in cytosolic calcium. In P. monodon, acute low-salt stress significantly enriches gene sets for calcium ion transmembrane transport, calmodulin binding and regulation of cytosolic calcium concentration, accompanied by increased activity of Ca2+/Mg2+-ATPase. The calcium wave activates a battery of calcium-sensitive kinases and phosphatases that fine-tune ion pumps through phosphorylation, restoring not only calcium balance but also sodium and potassium equilibrium. Strikingly, the cellular energy sensor AMPK rides along: hepatopancreatic AMPK-alpha transcripts increase roughly 28-fold just six hours after Pacific white shrimp are transferred from salinity 20 to salinity 3, linking osmotic calcium dynamics to metabolic reprogramming through calcium/calmodulin-dependent kinase kinase pathways.

The third perception layer is phospholipid signaling and membrane remodeling. Low salinity directly changes the physical state of cell membranes, particularly their fluidity and the activity of embedded proteins. Shrimp respond by adjusting membrane phospholipid composition, and over longer exposures they shift the ratio of saturated to unsaturated fatty acids to keep membranes supple. Phospholipase C-mediated hydrolysis of phosphoinositides generates second messengers such as IP3 and diacylglycerol, tuning membrane-protein interactions and the trafficking of ion-transport systems. The review frames this lipid turnover primarily as membrane remodeling that stabilizes integrity and preserves the function of osmoregulatory channels and pumps during cell swelling and volume recovery, a subtle but crucial distinction for interpreting the data.

Downstream of perception, three kinase networks translate stress signals into coordinated action. The MAPK pathway, with its ERK, JNK and p38 branches, governs cell growth, stress-responsive transcription and apoptosis; ERK supports proliferation while JNK and p38 can eliminate severely damaged cells and regulate inflammatory gene expression. The PI3K-Akt pathway acts as a survival engine: activated PI3K generates PIP3, which engages Akt, which in turn phosphorylates mTOR to promote anabolic metabolism while suppressing apoptotic proteins such as Bad and excluding FOXO transcription factors from the nucleus. Negative feedback through PTEN keeps the pathway from pathological overactivation. Meanwhile, the NF-kappaB pathway, engaged via I-kappa-B regulation and nuclear translocation, promotes immune, stress-response and anti-apoptotic gene programs. Together these modules drive gill-centered osmoregulation, immune priming and antioxidant control.

At the organ level, the gills take center stage. Gill ionocytes dynamically adjust ion absorption or excretion through core transport systems, most notably Na+/K+-ATPase and carbonic anhydrase. In dilute water, P. monodon ramps up ion uptake to raise internal osmotic pressure and prevent excessive water influx and cellular rupture. Na+/K+-ATPase burns ATP to exchange three sodium ions for two potassium ions across the membrane, maintaining the electrochemical gradient, and its activity typically rises under low salinity. Carbonic anhydrase catalyzes the reversible hydration of carbon dioxide, producing bicarbonate and protons that support the Na+/H+ exchanger and acid-base balance. Recent transcriptome work in P. monodon found markedly upregulated Na+/K+-ATPase subunits and elevated carbonic anhydrase transcripts under low salinity, alongside dynamic changes in actin and tubulin genes indicating cytoskeletal remodeling of gill epithelia. Antennal and maxillary glands contribute auxiliary water and ion excretion, though shrimp-specific mechanistic data for the latter remain thin.

The review also highlights two cellular quality-control systems that have received less attention. Autophagy, the degradation and recycling of damaged proteins and organelles, is initiated when energy stress activates AMPK and relieves mTOR-mediated inhibition of the Atg1 initiation complex. A cascade of Atg proteins, including the transmembrane Atg9 and the Atg7-Atg3 conjugation machinery that lipidates Atg8, builds autophagosomes that fuse with lysosomes to recycle cellular debris. In parallel, endoplasmic reticulum stress engages three sensor arms: PERK slows protein synthesis by phosphorylating eIF2-alpha while activating ATF4; ATF6 is cleaved in the Golgi to activate ER quality-control genes; and IRE1 splices XBP1 mRNA to boost chaperone and lipid biosynthesis. Proteins such as GRP78/BiP and CHOP decide whether the cell restores folding capacity or succumbs to apoptosis.

Salinity stress also reshapes immunity and redox balance. Under hyposalinity, shrimp upregulate scleroproteins that thicken the cuticle, lysozymes that dissolve bacterial cell walls, and antilipopolysaccharide factors that neutralize bacterial endotoxin. Recent transcriptomic data from P. monodon show that low salinity alone triggers upregulation of Toll-like receptor genes and downstream NF-kappaB components, suggesting osmotic stress primes innate immunity even without pathogens. Because immune effector processes and osmotic disturbance both elevate reactive oxygen species, antioxidant defense is tightly coupled to immune function. The Keap1-Nrf2 axis sits at the center: oxidative stress releases Nrf2 from Keap1, allowing it to enter the nucleus and bind antioxidant response elements, switching on superoxide dismutase, catalase, glutathione peroxidase and heme oxygenase-1, with feedback mechanisms preventing an overactive response.

The practical payoff is already visible in feeding trials. The review compiles nutritional interventions with direct experimental support for improved low-salinity resilience: cholesterol and phospholipids to stabilize membranes, vitamin C derivatives such as L-ascorbyl-2-polyphosphate to buffer oxidation, potassium and magnesium supplementation to enhance ion balance, and myo-inositol to support stress tolerance. Looking forward, the authors argue that identifying the true upstream osmosensors, integrating multi-omics with time-series designs, and exploiting chromosome-level genomes of L. vannamei, P. monodon and Marsupenaeus japonicus for comparative genomics and marker-assisted breeding will be essential. Genome editing remains technically difficult in crustaceans, so selective breeding and genomic selection carry near-term weight. As salinity fluctuations grow more frequent and less predictable, decoding the shrimp’s molecular playbook may prove decisive for building climate-resilient aquaculture systems.

Subject of Research: Molecular and physiological adaptations of penaeid shrimp to low-salinity stress

Article Title: Molecular and physiological adaptations to low-salinity stress in penaeid shrimp: a focus on Litopenaeus vannamei and Penaeus monodon

Article References: Huang, S., Zhou, F., Jiang, S., Li, E., & Li, Y. (2026). Molecular and physiological adaptations to low-salinity stress in penaeid shrimp: a focus on Litopenaeus vannamei and Penaeus monodon. Stress Biology, 6(1), Article 34. https://doi.org/10.1007/s44154-026-00295-4

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00295-4

Keywords: penaeid shrimp, Litopenaeus vannamei, Penaeus monodon, low-salinity stress, osmoregulation, GPCR signaling, calcium signaling, Na+/K+-ATPase, autophagy, endoplasmic reticulum stress, Nrf2 antioxidant pathway, aquaculture

PCOS affects an estimated one in ten women worldwide and is characterized by elevated androgens, irregular or absent ovulation, insulin resistance, and the hallmark appearance of cystic ovarian follicles. Current treatments, ranging from metformin to hormonal contraceptives, address individual symptoms but do not target the underlying inflammatory and oxidative stress machinery that appears to drive follicular dysfunction. Women with PCOS show elevated markers of oxidative damage and chronic low-grade inflammation, and previous studies have linked hyperandrogenism directly to impaired antioxidant defenses within the ovary itself. This dual burden of inflammation and oxidant injury damages granulosa cells, disrupts follicle maturation, and contributes to the anovulation that defines the syndrome.

The new study set out to test whether fucoxanthin could intervene on both fronts at once. The compound has attracted growing scientific interest over the past decade for its anti-obesity, anti-diabetic, and anti-inflammatory properties, and earlier work in macrophage cell models had shown that it can suppress NF-κB-driven cytokine production while simultaneously activating Nrf2, the master transcriptional regulator of cellular antioxidant responses. What remained unknown was whether this dual pharmacology would translate into meaningful therapeutic benefit in a living model of ovarian disease.

To answer that question, Ameen used the well-established dehydroepiandrosterone (DHEA)-induced mouse model of PCOS. Forty prepubertal female C57BL/6 mice, 25 days old, were divided into three groups. A control group of ten animals received subcutaneous injections of sesame oil, the vehicle. Fifteen mice received DHEA dissolved in sesame oil at a dose of 6 milligrams per 100 grams of body weight, which reliably induces the reproductive and metabolic hallmarks of PCOS. The final fifteen animals received the same DHEA regimen but were also fed standard chow supplemented with 0.2 percent fucoxanthin by weight for 21 days. The treatment window was chosen to span the critical period of follicular development, and all procedures were approved by the Ethics Committee of Koya University.

The results were striking across multiple dimensions. Perhaps most importantly, fucoxanthin restored normal estrous cyclicity, the mouse equivalent of the menstrual cycle, in 60 percent of the PCOS mice, compared with zero percent in the untreated DHEA group. Vaginal cytology, used to track the stages of the estrous cycle, revealed that the treated animals regained regular cycling patterns that had been completely abolished by chronic androgen excess. Microscopic examination of ovarian tissue stained with hematoxylin and eosin showed that the treated ovaries contained significantly more corpora lutea, the structures left behind after successful ovulation, and more large antral follicles approaching maturity. This histological picture indicates that fucoxanthin did not merely mask symptoms but actually rescued the ovulatory process itself.

The endocrine profile shifted in parallel. Serum testosterone, the primary androgen driving most PCOS symptoms, fell significantly in the fucoxanthin-treated group, along with luteinizing hormone and insulin-like growth factor-1, both of which are typically elevated in the syndrome. Follicle-stimulating hormone and insulin-like growth factor binding protein-1, which tend to be suppressed in PCOS, rose toward healthier levels. Insulin itself dropped significantly, and intraperitoneal insulin tolerance tests confirmed that the treated animals had improved sensitivity to the hormone, a critical finding given that insulin resistance affects a large majority of PCOS patients and amplifies ovarian androgen production through direct stimulation of theca cells.

At the tissue level, the molecular evidence pointed to a coordinated rebalancing of redox and inflammatory signaling. Ovarian malondialdehyde, a standard biomarker of lipid peroxidation and oxidative damage, decreased significantly with fucoxanthin treatment, while the activities of the antioxidant enzymes catalase and superoxide dismutase and the total antioxidant capacity of the tissue all increased. Pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, each of which is known to interfere with folliculogenesis and granulosa cell function, all fell to significantly lower levels in treated ovaries. These biochemical shifts suggest that fucoxanthin created a fundamentally healthier ovarian microenvironment, one in which developing follicles are no longer bombarded by inflammatory and oxidative insults.

Western blot analysis then revealed the mechanism underlying these effects. In the fucoxanthin-treated animals, ovarian expression of the PI3K regulatory subunit p85α and the ratio of phosphorylated to total AKT were both significantly upregulated, indicating enhanced activation of the insulin-signaling cascade that ultimately drives glucose uptake and cellular survival. Downstream of this pathway, the transcription factor Nrf2 and its target gene product heme oxygenase-1, or HO-1, were substantially elevated. Nrf2 functions as the cell’s primary antioxidant sensor: under oxidative stress it translocates to the nucleus and switches on a battery of detoxifying and antioxidant genes, including HO-1, which itself has potent anti-inflammatory activity. Simultaneously, the NF-κB p65 subunit, the master regulator of inflammatory gene transcription, was significantly downregulated. The simultaneous suppression of NF-κB and activation of Nrf2/HO-1 represents a molecular double hit that directly addresses the two pathogenic arms of PCOS identified in prior research.

The significance of this dual mechanism lies in the crosstalk between the two pathways. NF-κB and Nrf2 are not independent; they engage in mutual antagonism, with NF-κB activation suppressing Nrf2 signaling and vice versa. By enhancing PI3K/AKT signaling, which is known to promote Nrf2 nuclear translocation, fucoxanthin appears to tip this balance toward antioxidant defense while simultaneously starving the inflammatory pathway of its activating signals. Earlier studies had observed this pattern in isolated macrophages and in models of neuroinflammation and metabolic disease, but the new findings are the first to demonstrate it within ovarian tissue in the context of PCOS, and to link it to concrete reproductive outcomes such as restored ovulation and normalized hormonal cycling.

The insulin-sensitizing effect of fucoxanthin deserves particular attention in the PCOS context. Insulin resistance is now understood not merely as a metabolic complication of PCOS but as an active driver of the reproductive phenotype, since compensatory hyperinsulinemia stimulates ovarian androgen synthesis and reduces hepatic production of IGFBP-1, thereby increasing bioavailable IGF-1. By improving insulin sensitivity through the PI3K/AKT pathway, fucoxanthin may be interrupting this vicious cycle at multiple points simultaneously, lowering insulin itself, restoring IGFBP-1, reducing IGF-1 bioavailability, and thereby diminishing the androgenic drive that disrupts follicle selection and ovulation.

As with any preclinical mouse study, important caveats remain. The DHEA-induced model, while widely used, does not capture every aspect of human PCOS, and the 0.2 percent dietary fucoxanthin dose in mice cannot be directly translated to human supplementation without careful pharmacokinetic and safety studies. The 21-day treatment period is also relatively short compared with the chronic course of the syndrome in patients. Nevertheless, the consistency of the effects across hormonal, metabolic, histological, and molecular readouts, together with the strong mechanistic rationale from prior in vitro work, gives the findings unusual coherence for an early-stage study.

The research carries particular weight given the limitations of existing therapies. Metformin, the most commonly prescribed insulin-sensitizing agent in PCOS, has been shown to activate Nrf2/HO-1 signaling in granulosa cells, but its gastrointestinal side effects limit adherence, and it does not reliably restore ovulation in all patients. Antioxidant supplements such as curcumin, astaxanthin, and quercetin have shown promise in animal models but typically target either inflammation or oxidative stress, not both. A natural compound that can be delivered through the diet and that simultaneously dampens NF-κB, activates Nrf2/HO-1, restores insulin signaling, and normalizes reproductive cyclicity would represent a genuinely multi-targeted therapeutic option for a syndrome that has long resisted single-mechanism approaches.

For the millions of women living with PCOS, the study offers an early but tangible signal that a pigment from the ocean’s kelp forests might one day complement, or in some cases partially replace, the pharmaceutical toolkit. Clinical trials in human patients remain the essential next step, but the molecular logic uncovered in this work provides a clear roadmap for such studies, with well-defined biomarkers including testosterone, LH, insulin, ovarian antioxidant enzyme activity, and NF-κB and Nrf2 pathway activation available to assess whether the marine compound can deliver the same coordinated therapeutic effect in people. The research received no specific external funding, and the author reports no competing interests.